Indeed, inhibition of serine palmitoyltransferase (SPT), the rate-limiting step in ceramide biosynthesis, or deletion of its subunits Sptlc1 or Sptlc2 in obese mice limits the formation of these obesogenic sphingolipids and consequently reduces diet-induced obesity, improves glucose tolerance and insulin resistance, preventing the progression to NASH [[12], [13], [14]]. Here, SPTLC2 is linked to metabolic dysfunction-associated steatohepatitis.